Argenx signs $1.5B pact to turn Unnatural Products' macrocyclic peptides to 'undruggable' targets - Fierce Biotech
Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian biotech Unnatural Products to hunt down “undruggable” targets. | Argenx wants to get in on the macrocyclic peptide action, penning a deal …
Comments